State of the science: neonatal bacterial infection in the early 21st century
Abstract
Bacterial infections continue to cause significant neonatal morbidity and mortality, especially in small preterm neonates in the neonatal intensive care unit. Maternal and newborn risk factors can be used to prevent newborn infection and initiate early clinical assessments, laboratory diagnostic tests, and antimicrobial agent therapies. Early-onset and late-onset infections have different clinical patterns; however, each must be recognized as soon as possible in order to optimize outcomes. Antibiotics have long been the mainstay of treatment but organism resistance and weak immune system functioning of very premature newborns makes treatment challenging. Research continues on other markers for infection that may lead to more rapid diagnosis. The discovery of new therapies to improve newborn immune system function promises further improvement in outcomes of newborn infection. This article gives an overview of the state of diagnosis and treatment of newborn infection.
References
Elevated gene expression of interleukin-8 in cord blood is a sensitive marker for neonatal infection
Citations
A multicentred clinical improvement project among preterm population evaluation of current practices
Related Concepts
Related Feeds
Antifungals (ASM)
An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.
Antifungals
An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.